Merck Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III KEYNOTE-775/Study 309 trial for the Treatment of Advanced Endometrial Cancer at SGO

 Merck Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III KEYNOTE-775/Study 309 trial for the Treatment of Advanced Endometrial Cancer at SGO

Merck Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III KEYNOTE-775/Study 309 trial for the Treatment of Advanced Endometrial Cancer at SGO

Shots:

  • The P-III KEYNOTE-775/Study 309 trial involves assessing Keytruda (200mg, IV, q3w) + Lenvima (20mg, PO, qd) vs CT Doxorubicin (60 mg/m2, IV, q3wks.) or Paclitaxel (80 mg/m2, IV, 28-day cycle) in a ratio (1:1) in patients with advanced EC following one prior Pt -based regimen in any setting
  • Results: 1EPs in all-comer population @ Median follow-up 11.4 mos., 44% reduction in the risk of disease progression or death; median PFS (7.2 vs 3.8 mos)., 38% reduction in the risk of death; median OS (18.3 vs 11.4 mos.)
  • In the pMMR subgroup, 40% reduction in the risk of disease progression or death; median PFS (6.6 vs 3.8 mos); 32% reduction in the risk of death; median OS (17.4 vs 12mos.)

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Law.com

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post